Interferon γ-Induced Protein10 Kinetics in Treatment-Naive Versus Treatment-Experienced Patients Receiving Interferon-Free Therapy for Hepatitis C Virus Infection: Implications for the Innate Immune Response

被引:20
|
作者
Lin, Jennifer C. [1 ]
Habersetzer, Francois [7 ,8 ,9 ]
Rodriguez-Torres, Maribel [6 ]
Afdhal, Nezam [3 ]
Lawitz, Eric J. [4 ]
Paulson, Matthew S. [2 ]
Zhu, Yanni [2 ]
Subramanian, Gangadharan Mani [2 ]
McHutchison, John G. [2 ]
Sulkowski, Mark [5 ]
Wyles, David L. [1 ]
Schooley, Robert T. [1 ]
机构
[1] Univ Calif San Diego, La Jolla, CA 92093 USA
[2] Gilead Sci, Foster City, CA USA
[3] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[4] Alamo Med Res, San Antonio, TX USA
[5] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[6] Fdn Invest Diego, San Juan, PR USA
[7] Hop Univ Strasbourg, Strasbourg, France
[8] INSERM 1110, Strasbourg, France
[9] Univ Strasbourg, Strasbourg, France
来源
JOURNAL OF INFECTIOUS DISEASES | 2014年 / 210卷 / 12期
基金
美国国家卫生研究院;
关键词
IP-10; hepatitis C; direct-acting antiviral therapy; innate immunity; INDUCIBLE PROTEIN-10; INFLAMMATION; RIBAVIRIN; CORRELATE; FIBROSIS; PREDICTS;
D O I
10.1093/infdis/jiu325
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We measured interferon gamma-induced protein 10 (IP-10) levels in 428 patients at baseline, week 1, and week 2 of all-oral treatment for hepatitis C virus (HCV) infection. An increased baseline IP-10 level was associated with a T allele in the IL28B gene, an increased alanine aminotransferase level in treatment-naive but not experienced patients, and an increased body mass index. At week 1, the mean decline in plasma IP-10 levels was the same in treatment-naive and treatment-experienced patients (-49%), whereas during week 2 the mean decline in IP-10 levels in treatment-naive patients (-14%) was significantly larger than in treatment-experienced patients (-2%; P =.0176). IP-10 thus may be a surrogate marker of the rate of intracellular viral replication complex decay.
引用
收藏
页码:1881 / 1885
页数:5
相关论文
共 50 条
  • [21] C-SURFER: GRAZOPREVIR PLUS ELBASVIR IN TREATMENT-NAIVE AND TREATMENT-EXPERIENCED PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1 INFECTION AND CHRONIC KIDNEY DISEASE
    Bruchfeld, Annette
    Roth, David
    Nelson, David
    Liapakis, AnneMarie
    Silva, Marcelo
    Monsour, Howard
    Martin, Paul
    Pol, Stanislas
    Londono, Maria-Carlota
    Hassanein, Tarek
    Zamor, Philippe
    Zuckerman, Eli
    Zhao, Yue
    Robertson, Michael
    Wahl, Janice
    Barr, Eliav
    Greaves, Andwayne
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2015, 30
  • [22] Modeling Viral Kinetics and Treatment Outcome During Alisporivir Interferon-Free Treatment in Hepatitis C Virus Genotype 2 and 3 Patients
    Guedj, Jeremie
    Yu, Jing
    Levi, Micha
    Li, Bin
    Kern, Steven
    Naoumov, Nikolai V.
    Perelson, Alan S.
    HEPATOLOGY, 2014, 59 (05) : 1706 - 1714
  • [23] Regulation of the response to interferon therapy through innate immune tolerance during hepatitis C virus infection
    Lau, Daryl T. Y.
    Chen, Jie
    Saito, Takeshi
    Crochet, Nanette
    Zhang, Yuhong
    Holder, Sharon
    Gale, Michael, Jr.
    CYTOKINE, 2010, 52 (1-2) : 66 - 66
  • [24] ADDITIONAL BOCEPREVIR INCREASES SUSTAINED VIROLOGICAL RESPONSE (SVR) RATES IN TREATMENT-NAIVE AND TREATMENT-EXPERIENCED CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1 INFECTION
    Desai, Mitesh
    SEXUALLY TRANSMITTED INFECTIONS, 2011, 87 (05) : 449 - 449
  • [25] OVERCOMING BARRIERS TO INTERFERON-FREE HEPATITIS C VIRUS THERAPY DELIVERY IN DRUG AND ALCOHOL TREATMENT SETTINGS
    Dunlop, Adrian J.
    Keats, Julian
    DRUG AND ALCOHOL REVIEW, 2016, 35 : 15 - 15
  • [26] Consensus interferon in combination with gamma interferon and/or ribavirin leads to a significant response in treatment-naive hepatitis C genotype 1 patients
    Kaiser, S
    Hass, H
    Gregor, M
    HEPATOLOGY, 2005, 42 (04) : 277A - 277A
  • [27] THE USE OF SINGLE-ARM EVIDENCE IN THE COMPARATIVE EFFICACY OF INTERFERON-FREE ANTIVIRALS FOR TREATMENT-NAIVE HEPATITIS C GENOTYPE 1
    Druyts, E.
    Kanters, S.
    Toor, K.
    Thorlund, K.
    Mills, E. J.
    VALUE IN HEALTH, 2015, 18 (07) : A576 - A576
  • [28] High dose induction therapy with consensus interferon and ribavirin for treatment-naive patients with hepatitis C.
    Kaiser, S
    Hass, H
    Gregor, M
    HEPATOLOGY, 2002, 36 (04) : 362A - 362A
  • [29] Interferon therapy in haemodialysis patients with acute hepatitis C virus infection and factors that predict response to treatment
    Gürsoy, M
    Gür, G
    Arslan, H
    Özdemir, N
    Boyacioglu, S
    JOURNAL OF VIRAL HEPATITIS, 2001, 8 (01) : 70 - 77
  • [30] Hepatitis B Virus Reactivation in Patients Receiving Interferon-Free Direct-Acting Antiviral Agents for Chronic Hepatitis C Virus Infection
    Liu, Chen-Hua
    Liu, Chun-Jen
    Su, Tung-Hung
    Fang, Yu-Jen
    Yang, Hung-Chih
    Chen, Pei-Jer
    Chen, Ding-Shinn
    Kao, Jia-Horng
    OPEN FORUM INFECTIOUS DISEASES, 2017, 4 (01):